The discovery of the rapid antidepressant effects of the dissociative anaesthetic ketamine,
an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is arguably the most important …

Background The glutamatergic modulator ketamine has created a blueprint for studying
novel pharmaceuticals in the field. Recent studies suggest that “classic” serotonergic …

This study tested the efficacy of repeated intravenous ketamine doses to reduce symptoms
of posttraumatic stress disorder (PTSD). Veterans and service members with PTSD (n= 158) …

The discovery of ketamine as a rapid and robust antidepressant marks the beginning of a
new era in the treatment of psychiatric disorders. Ketamine is thought to produce rapid and …

Targeting receptor proteins, such as ligand-gated ion channels and G protein-coupled
receptors, has directly enabled the discovery of most drugs developed to modulate receptor …

Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-
Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for …

Background Preclinical studies have indicated that the ketamine metabolite (2R, 6R)-
hydroxynorketamine (HNK) is a rapid-acting antidepressant drug with limited dissociation …

Suicide is the second leading cause of death in the United States among individuals aged
10–24, and severe youth depression is often refractory to the current standards of care …

Vesicular glutamate transporters (VGLUTs) control quantal size of glutamatergic
transmission and have been the center of numerous studies over the past two decades …

There are several hypotheses concerning the underlying pathophysiological mechanisms of
major depression, which centre largely around adaptive changes in neuronal transmission …